Business Standard

Tuesday, December 24, 2024 | 11:04 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Glenmark Pharma submits application for new drug Ryaltris with USFDA

Ryaltris is for treatment of seasonal allergic rhinitis (SAR) in patients 12 years of age and older

Pharmaceuticals, drugs, pharma industry, medical, health, lab
Premium

Press Trust of India New Delhi
Glenmark Pharmaceuticals has submitted a new drug application with the US health regulator for its nasal spray Ryaltris.

Ryaltris is for treatment of seasonal allergic rhinitis (SAR) in patients 12 years of age and older.

"The company has submitted a new drug application (NDA) to the US Food & Drug Administration (USFDA) for... respiratory pipeline candidate Ryaltris, an investigational fixed-dose combination nasal spray of an antihistamine and a steroid," Glenmark Pharmaceuticals said in a BSE filing.

Ryaltris (olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)), formerly GSP 301 Nasal Spray, has been conditionally accepted by the USFDA as the

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in